VOLITIONRX LIMITED


Associated tags: Volition, NYSE, Cancer, Sepsis, Research, Conference call

VolitionRx Awarded $1.5 Million in Non-Dilutive Funding

Retrieved on: 
Wednesday, August 3, 2022
Failure, Human, Securities Act of 1933, Diagnosis, Security (finance), Annual report, COVID-19, Quality of life, Internet, Life, Wallonia, NYSE, Securities Exchange Act of 1934, Patient, U.S. Securities and Exchange Commission, Cancer, Volition (linguistics), Animal, Disease, Neutrophil extracellular traps, Technology, Research, Science, Forward-looking statement, Adoption, Sepsis, Pharmaceutical industry, Medical device, EU, Nucleosome, Volition

HENDERSON, Nev., Aug. 3, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced it has been awarded a further $1.5 million non-dilutive funding from Namur Invest Capital Risk in Belgium.

Key Points: 
  • HENDERSON, Nev., Aug. 3, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced it has been awarded a further $1.5 million non-dilutive funding from Namur Invest Capital Risk in Belgium.
  • "We will be working with centers of excellence worldwide providing leading clinicians and researchers with exclusive, early access to our Nu.Q product range.
  • Namur Invest's loan is the latest grant from agencies within the Walloon Region, amounting to more than $14 million in non-dilutive funding since 2016.
  • Nucleosomics and Nu.Q and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries.

VolitionRx Limited Announces Pricing of $6 Million Underwritten Public Offering of Common Stock

Retrieved on: 
Friday, July 29, 2022
Sale, U.S. Securities and Exchange Commission, Forward-looking statement, NYSE, SEC, Research, Telephone, Risk, SEC filing, Sepsis, Securities Act of 1933, Securities Exchange Act of 1934, Neutrophil extracellular traps, COVID-19, Prospectus, Volition, Quality of life, Attention, Disease, Company, Science, Cancer, Patient, Security (finance), Life, Annual report, Volition (company), Suite, Form, Nucleosome

HENDERSON, Nev., July 29, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $2.00 per share.

Key Points: 
  • HENDERSON, Nev., July 29, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $2.00 per share.
  • The gross proceeds to Volition from the offering, before deducting the underwriting commissions and other estimated offering expenses payable by Volition, are expected to be $6 million.
  • The offering is expected to close on or about August 2, 2022, subject to the satisfaction of customary closing conditions.
  • Nucleosomics and Nu.Q and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries.

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock

Retrieved on: 
Thursday, July 28, 2022
Sale, U.S. Securities and Exchange Commission, NYSE, SEC, SEC filing, Research, Telephone, Royal Securities Corporation, Sepsis, Neutrophil extracellular traps, COVID-19, Prospectus, Volition, Quality of life, Attention, Disease, Company, Science, Cancer, Patient, Security (finance), Life, Suite, Form, Nucleosome

HENDERSON, Nev., July 28, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today that it has commenced an underwritten public offering of its common stock.

Key Points: 
  • HENDERSON, Nev., July 28, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today that it has commenced an underwritten public offering of its common stock.
  • All of the shares of common stock are being offered by Volition.
  • In addition, Volition intends to grant the underwriter in the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions.
  • The final terms of the proposed offering will depend on market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

VolitionRx Limited Announces First Quarter 2022 Financial Results and Business Update

Retrieved on: 
Wednesday, May 11, 2022
Cancer, Quality, Company, Disease, Capital market, Chromatin, Nu, New, 2021 Essex County Council election, Patient, Science, Quality of life, Lung cancer, Point-of-care testing, Proteomics, COVID-19, Point, Research, Mass spectrometry, Epigenetics, Marketing, Life, GenomeWeb, Conference call, NYSE, Software development process, Technology, Sale, Colorectal cancer, NETS, Lung, Animal, Sepsis, Diagnosis, Factor X, Achievement, Video game, Pharmaceutical industry, Sales, Veterinary medicine, Video game console, Medical device, Online shopping, Neutrophil extracellular traps, Conference, Volition, Nucleosome

AUSTIN, Texas, May 11, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2022. Volition management will host a conference call tomorrow, May 12 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.

Key Points: 
  • Conference call to discuss financial and operational results scheduled for Thursday, May 12, at 8:30 a.m. U.S. Eastern Time
    AUSTIN, Texas, May 11, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2022.
  • Volition management will host a conference call tomorrow, May 12 at 8:30 a.m. U.S. Eastern Time to discuss these results.
  • Cash and cash equivalents as of March 31, 2022, totaled approximately $23.7 million compared with $20.6 million as of December 31, 2021.
  • The call will provide an update on important events which have taken place in the first quarter of 2022 and upcoming milestones.

VolitionRx Limited Schedules First Quarter 2022 Earnings Conference Call and Business Update

Retrieved on: 
Friday, May 6, 2022
COVID-19, New, NYSE, Patient, Conference call, Investor relations, Quality of life, Capital market, Disease, Science, Life, Research, Neutrophil extracellular traps, Cancer, Sepsis, Reinsurance, Online shopping, Medical device, Nucleosome, Conference, Volition

AUSTIN, Texas, May 6, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday May 12, at 08.30 a.m. Eastern Time to discuss its financial and operating results for the first quarter 2022, in addition to providing a business update. Volition previously announced it will host a Capital Markets Day at the New York Stock Exchange on Friday May 13, details of said event can also be found below.

Key Points: 
  • The call will provide an update on important events which have taken place in the first quarter of 2022 and upcoming milestones.
  • A live audio webcast of the conference call will also be available on the investor relations page of Volition's corporate website at http://ir.volition.com .
  • In addition, a telephone replay of the call will be available until May 25, 2022.
  • Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

VolitionRx Limited to Host Capital Markets Day on Friday May 13

Retrieved on: 
Thursday, May 5, 2022
COVID-19, Twitter, Patient, HERE, Animal, Cancer, Human, Quality of life, LinkedIn, Disease, Science, Life, Technology, Research, Neutrophil extracellular traps, Sepsis, Volition, Online shopping, Medical device, Nucleosome, Facebook

The event will be webcast and the presentations will be posted to Volition's website.

Key Points: 
  • The event will be webcast and the presentations will be posted to Volition's website.
  • Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life.
  • Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
  • For more information about Volition, visit Volition's website or connect with us via Twitter , LinkedIn , and Facebook .

Heska Corporation Signs Exclusive Agreement to Introduce Nu.Q® Vet Cancer Screening Test, First-Ever Point of Care Cancer Screen

Retrieved on: 
Tuesday, March 29, 2022
Human, Family, Informatics, Malignancy, National Cancer Institute, NYSE, Caregiver, Volition (company), Lymphoma, Research, Software, Sepsis, Securities Exchange Act of 1934, Securities Act of 1933, Dog, Veterinarian, Solution, Annual report, Volition, Disease, Security (finance), HSKA, PETS, Health, Quality of life, Industry, U.S. Securities and Exchange Commission, Science, Animal, National, Morgan Stanley, Cancer, Life, NASDAQ, Investment, Forward-looking statement, Immunotherapy, Multimedia, License, Name, Neutrophil extracellular traps, Patient, Texas A&M University, Interview, COVID-19, Professor, Pharmaceutical industry, Vaccine, Medical imaging, Management, Mobile phone, Medical device, International, Nucleosome

In the U.S. alone, the National Cancer Institute estimates that six million new cancer diagnoses are made in dogs each year.

Key Points: 
  • In the U.S. alone, the National Cancer Institute estimates that six million new cancer diagnoses are made in dogs each year.
  • To address the growing need to battle malignancy in companion animals, Heska is excited to introduce the first-ever cancer screen to veterinarians at the point of care.
  • Under the terms of the agreement, Heska intends to adapt and commercialize the Nu.Q Vet Cancer Screening Test for canine screening and monitoring at the point of care exclusively on Heska's analyzers and test platforms.
  • Heska's Nu.Q Vet Cancer Screening Test targets one of the most critical challenges in pet healthcare.

Volition Signs Exclusive $28 million License and Supply Agreement with Heska Corporation to Distribute Nu.Q® Vet Cancer Screening Test at the Point of Care

Retrieved on: 
Tuesday, March 29, 2022
Human, Family, National Cancer Institute, NYSE, Caregiver, Volition (linguistics), Lymphoma, Research, Software, Technology, Sepsis, Securities Exchange Act of 1934, Securities Act of 1933, Dog, Solution, Annual report, Nu, Disease, Security (finance), Veterinarian, HSKA, PETS, Achievement, Health, Quality of life, Industry, U.S. Securities and Exchange Commission, Science, Animal, National, Morgan Stanley, Cancer, Life, NASDAQ, Investment, III, Forward-looking statement, Immunotherapy, Multimedia, Hemangiosarcoma, License, Name, National Food Security Act, 2013, Neutrophil extracellular traps, Patient, Texas A&M University, COVID-19, Professor, Pharmaceutical industry, Vaccine, Medical imaging, Medical device, Mobile phone, International, Volition, Nucleosome

In exchange for granting Heska these exclusive worldwide rights to sell the Nu.Q Vet Cancer Test, Volition will receive:

Key Points: 
  • In exchange for granting Heska these exclusive worldwide rights to sell the Nu.Q Vet Cancer Test, Volition will receive:
    up to $18 million based upon the achievement of near/mid-term milestones.
  • Volition's licensing agreement with Heska grants exclusive rights to commercialize the Nu.Q Vet Cancer Screening Test for canine cancer screening and monitoring at the point of care.
  • Volition's Nu.Q Vet Cancer Screening Test will operate on Heska's proprietary Element i+ Immunodiagnostic Analyzer, a point of care platform.
  • Heska's Nu.Q Vet Cancer Screening Test targetsone of the most critical challenges in pet healthcare.

Volition presents study data at ASCO GI 2022 on circulating nucleosomes for the detection of colorectal cancer and high-risk advanced adenomas

Retrieved on: 
Thursday, January 20, 2022
Securities Exchange Act of 1934, Forward-looking statement, Name, Nucleosome, Publication, Disease, U.S. Securities and Exchange Commission, Volition (linguistics), Cancer, Annual report, Security (finance), Securities Act of 1933, Medical device, Video game console, Volition

Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "can," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements.

Key Points: 
  • Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "can," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements.
  • For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations.
  • These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict.
  • All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

VolitionRx Limited Schedules Third Quarter 2021 Earnings Conference Call and Business Update

Retrieved on: 
Monday, November 8, 2021
Quality of life, Science, Investor relations, Disease, COVID-19, Research, Sepsis, Cancer, Neutrophil extracellular traps, NYSE, Patient, Life, Pharmaceutical industry

AUSTIN, Texas, Nov. 8, 2021 /PRNewswire/ --VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday, November 11, at 8:00 a.m. Eastern time to discuss its financial and operating results for the third quarter of 2021, in addition to providing a business update.

Key Points: 
  • AUSTIN, Texas, Nov. 8, 2021 /PRNewswire/ --VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday, November 11, at 8:00 a.m. Eastern time to discuss its financial and operating results for the third quarter of 2021, in addition to providing a business update.
  • The call will provide an update on recent developments and Volition's activities, including details of new and ongoing clinical trials, important events which have taken place in the third quarter of 2021, and milestones for the remainder of 2021 and beyond.
  • A live audio webcast of the conference call will also be available on the investor relations page of Volition's corporate website at http://ir.volition.com .
  • In addition, a telephone replay of the call will be available until November 25, 2021.